Annual reports filed by certain Canadian issuers pursuant to Section 15(d) and Rule 15d-4

Note 11 - Research and Development

v3.8.0.1
Note 11 - Research and Development
 12 Months Ended
Dec. 31, 2017
Statement Line Items [Line Items]  
Disclosure of research and development expense [text block]
11.
 Research and Development:
 
Components of research and development expenses are as follows:
 
    Year ended
December 31,
2017		     Year ended
December 31,
2016		     Year ended
December 31,
2015		  
          As recast
(note 3(b))		     As recast
(note 3(b))		  
                   
Research and Development excluding salaries   $
4,573
     $
4,860
     $
3,131
  
CrystalGenomics Option Fee (a)    
-
      
1,000
      
-
  
Salaries    
1,451
      
1,691
      
1,528
  
Stock-based compensation    
214
      
247
      
183
  
Depreciation of equipment    
36
      
36
      
23
  
    $
6,274
     $
7,834
     $
4,865
  
 
During the year ended
December 
31,
2016,
the Company paid
$1.0
million to CrystalGenomics for an option fee related to the
CG’806
technology.